Tomoko Takeda
Ajinomoto
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tomoko Takeda.
Gastroenterology | 2009
Ayatoshi Andou; Tadakazu Hisamatsu; Susumu Okamoto; Hiroshi Chinen; Nobuhiko Kamada; Taku Kobayashi; Masaki Hashimoto; Tomohisa Okutsu; Kazutaka Shimbo; Tomoko Takeda; Hideki Matsumoto; Atsushi Sato; Hiroshi Ohtsu; Manabu Suzuki; Toshifumi Hibi
BACKGROUND & AIMS Elemental diet (ED) is effective for human Crohns disease (CD). Although some of this effectiveness may be due to its low antigenic load and low fat content, the mechanisms remain unclear. We sought to assess the role of histidine, one of the constituent amino acids of ED, in controlling colitis. METHODS The interleukin (IL)-10-deficient (IL-10(-/-)) cell transfer model of colitis was used. SCID mice with colitis induced by transfer of IL-10(-/-) cells were maintained on experimented diets containing either single amino acids or a mixture. The severity of colitis was assessed by wet colon weight. Colonic tumor necrosis factor (TNF)-alpha messenger RNA (mRNA) expression was detected by quantitative reverse-transcription polymerase chain reaction. Mouse peritoneal macrophages were stimulated by lipopolysaccharides (LPS), with or without amino acids. The concentration of cytokines in the supernatant was determined by enzyme-linked immunosorbent assay. Inhibitor of nuclear factor (NF)-kappaB-alpha and nuclear p65 were confirmed by immunoblotting. RESULTS In the IL-10(-/-) transfer model, dietary histidine, but not alanine, reduced histologic damage and colon weight and TNF-alpha mRNA expression. Histidine inhibited LPS-induced TNF-alpha and IL-6 production by mouse macrophages in a concentration-dependent manner, whereas alanine or histidine-related metabolites had no such effect. Histidine inhibited LPS-induced NF-kappaB in macrophages. CONCLUSIONS These results showed that histidine could be a novel therapeutic agent for CD by inhibition of NF-kappaB activation, following down-regulation of proinflammatory cytokine production by macrophages. Thus, our studies provided new insights into the roles of amino acid metabolism in the pathophysiology of CD and for therapeutic strategies.
European Journal of Pharmacology | 2002
Akira Takahara; Hajime Koganei; Tomoko Takeda; Seinosuke Iwata
The in vivo antisympathetic property of a dual L/N-type Ca(2+) channel blocker cilnidipine compared with that of typical N-type Ca(2+) channel blockers has never been clarified. We investigated the effects of the drug on a sympathetic nerve-mediated vascular response and vasodilating action in rats in comparison with those of an N-type Ca(2+) channel blocker omega-conotoxin MVIIA. In pithed rats, omega-conotoxin MVIIA preferentially suppressed the sympathetic nerve stimulation-induced pressor response, whereas cilnidipine suppressed the pressor response induced by sympathetic nerve stimulation and angiotensin II. In anesthetized rats, cilnidipine or omega-conotoxin MVIIA decreased mean blood pressure, while heart rate was decreased by omega-conotoxin MVIIA, but slightly increased by cilnidipine. These results suggest that cilnidipine can affect sympathetic N-type Ca(2+) channels in addition to vascular L-type Ca(2+) channels in antihypertensive doses in the rat in vivo. The antisympathetic activity of cilnidipine is not excessive for an antihypertensive drug in comparison with that of omega-conotoxin MVIIA.
Bioorganic & Medicinal Chemistry Letters | 2008
Takashi Yamamoto; Seiji Niwa; Seiji Ohno; Munetaka Tokumasu; Yoko Masuzawa; Chika Nakanishi; Akira Nakajo; Tomoyuki Onishi; Hajime Koganei; Shinichi Fujita; Tomoko Takeda; Morikazu Kito; Yukitsugu Ono; Yuki Saitou; Akira Takahara; Seinosuke Iwata; Masataka Shoji
In order to find an injectable and selective N-type calcium channel blocker, we have performed the structure-activity relationship (SAR) study on the 2-, 5-, and 6-position of 1,4-dihydropyridine-3-carboxylate derivative APJ2708 (2), which is a derivative of Cilnidipine and has L/N-type calcium channel dual inhibitory activities. As a consequence of the optimization, 6-dimethylacetal derivative 7 was found to have an effective inhibitory activity against N-type calcium channels with more than 170-fold lower activity for L-type channel compared to that of APJ2708.
Bioorganic & Medicinal Chemistry Letters | 2011
Takashi Yamamoto; Seiji Ohno; Seiji Niwa; Munetaka Tokumasu; Masako Hagihara; Hajime Koganei; Shinichi Fujita; Tomoko Takeda; Yuki Saitou; Satoshi Iwayama; Akira Takahara; Seinosuke Iwata; Masataka Shoji
An efficient asymmetric synthesis of 1,4-dihydropyridine derivatives is described. The key step is the stereoselective Michael addition using t-butyl ester of L-valine as a chiral auxiliary to achieve good ee (>95% for all the tested experiments) and moderate yield. With this method, (+)-4-(3-chlorophenyl)-6-dimethoxymethyl-2-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid cinnamyl ester was obtained and was characterized as a promising N-type calcium channel blocker with improved selectivity over L-type compared to its (-)- and racemic isomers.
Neuropsychopharmacology | 2015
Nobuhiro Kawai; Noriaki Sakai; Masashi Okuro; Sachie Karakawa; Yosuke Tsuneyoshi; Noriko Kawasaki; Tomoko Takeda; Makoto Bannai; Seiji Nishino
The use of glycine as a therapeutic option for improving sleep quality is a novel and safe approach. However, despite clinical evidence of its efficacy, the details of its mechanism remain poorly understood. In this study, we investigated the site of action and sleep-promoting mechanisms of glycine in rats. In acute sleep disturbance, oral administration of glycine-induced non-rapid eye movement (REM) sleep and shortened NREM sleep latency with a simultaneous decrease in core temperature. Oral and intracerebroventricular injection of glycine elevated cutaneous blood flow (CBF) at the plantar surface in a dose-dependent manner, resulting in heat loss. Pretreatment with N-methyl-D-aspartate (NMDA) receptor antagonists AP5 and CGP78608 but not the glycine receptor antagonist strychnine inhibited the CBF increase caused by glycine injection into the brain. Induction of c-Fos expression was observed in the hypothalamic nuclei, including the medial preoptic area (MPO) and the suprachiasmatic nucleus (SCN) shell after glycine administration. Bilateral microinjection of glycine into the SCN elevated CBF in a dose-dependent manner, whereas no effect was observed when glycine was injected into the MPO and dorsal subparaventricular zone. In addition, microinjection of D-serine into the SCN also increased CBF, whereas these effects were blocked in the presence of L-701324. SCN ablation completely abolished the sleep-promoting and hypothermic effects of glycine. These data suggest that exogenous glycine promotes sleep via peripheral vasodilatation through the activation of NMDA receptors in the SCN shell.
Bioorganic & Medicinal Chemistry Letters | 2012
Takashi Yamamoto; Seiji Niwa; Munetaka Tokumasu; Tomoyuki Onishi; Seiji Ohno; Masako Hagihara; Hajime Koganei; Shinichi Fujita; Tomoko Takeda; Yuki Saitou; Satoshi Iwayama; Akira Takahara; Seinosuke Iwata; Masataka Shoji
A structure-activity relationship study of 6-unsubstituted-1,4-dihydropyridine and 2,6-unsubstituted-1,4-dihydropyridine derivatives was conducted in an attempt to discover N-type calcium channel blockers that were highly selective over L-type calcium channel blockers. Among the tested compounds, (+)-4-(3,5-dichloro-4-methoxy-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-cinnamyl ester was found to be an effective and selective N-type calcium channel blocker with oral analgesic potential.
Journal of Nutrition | 2016
Hiroyuki Kato; Sayako Nakano; Yoshiko Inoue; Tomoko Takeda; Kyoko Miura; Taro Nakamura; Katsuya Suzuki; Makoto Bannai
BACKGROUND The indicator amino acid oxidation (IAAO) method has contributed to establishing protein and amino acid (AA) requirements by determining the optimal protein and AA intake that maximizes whole-body protein synthesis. However, it has not been used with endurance-trained subjects. OBJECTIVE This study aimed to determine the optimal AA intake immediately after endurance exercise and at rest in endurance-trained rats by using the IAAO method. METHODS Four-week-old male Fischer rats were divided into a sedentary (SED) group and a trained (TR) group, which underwent treadmill training 5 d/wk for 6 wk at 26 m/min for 60 min/d. On the metabolic trial day, half of the TR group was provided with test diets after daily treadmill running (TR-PostEx). The other half of the TR group (TR-Rest) and all of the SED group were provided with test diets while at rest. The test diets contained different amounts of AAs (3.3-37.3 g ⋅ kg(-1) ⋅ d(-1)). Phenylalanine in the test diet was replaced with L-[1-(13)C]phenylalanine. The phenylalanine oxidation rate (PheOx) was determined with (13)CO2 enrichment in breath, CO2 excretion rate, and enrichment of phenylalanine in blood during the feeding period. The optimal AA intake was determined with biphasic mixed linear regression crossover analysis for PheOx, which identified a breakpoint at the minimal PheOx in response to graded amounts of AA intake. RESULTS The optimal AA intake in the TR-PostEx group (26.8 g ⋅ kg(-1) ⋅ d(-1); 95% CI: 21.5, 32.1 g ⋅ kg(-1) ⋅ d(-1)) was significantly higher than in the SED (15.1 g ⋅ kg(-1) ⋅ d(-1); 95% CI: 11.1, 19.1 g ⋅ kg(-1) ⋅ d(-1)) and TR-Rest (13.3 g ⋅ kg(-1) ⋅ d(-1); 95% CI: 10.9, 15.7 g ⋅ kg(-1) ⋅ d(-1)) groups, which did not differ. CONCLUSIONS Greater AA intake is required to maximize whole-body protein synthesis immediately after endurance exercise than at rest, but not at rest in endurance-trained rats.
Digestive Diseases and Sciences | 2009
Takayuki Kajiura; Tomoko Takeda; Shinji Sakata; Mitsuo Sakamoto; Masaki Hashimoto; Hideki Suzuki; Manabu Suzuki; Yoshimi Benno
Bioorganic & Medicinal Chemistry Letters | 2006
Takashi Yamamoto; Seiji Niwa; Seiji Ohno; Tomoyuki Onishi; Hiroyuki Matsueda; Hajime Koganei; Hisayuki Uneyama; Shinichi Fujita; Tomoko Takeda; Morikazu Kito; Yukitsugu Ono; Yuki Saitou; Akira Takahara; Seinosuke Iwata; Masataka Shoji
Bioorganic & Medicinal Chemistry | 2006
Takashi Yamamoto; Seiji Niwa; Satoshi Iwayama; Hajime Koganei; Shinichi Fujita; Tomoko Takeda; Morikazu Kito; Yukitsugu Ono; Yuki Saitou; Akira Takahara; Seinosuke Iwata; Hiroshi Yamamoto; Masataka Shoji